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Review

Harnessing preclinical mouse models
to inform human clinical cancer trials
David H. Gutmann,1 Kim Hunter-Schaedle,2 and Kevin M. Shannon3
2Children’s

1Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Tumor Foundation, New York, New York, USA. 3Department of Pediatrics, UCSF, San Francisco, California, USA.

The urgent need for better cancer treatments has stimulated interest in employing small-animal models to evaluate
potential drug therapies. Robust mouse models of many human cancers have been generated using sophisticated
technologies for engineering germ-line mutations. As we enter into an age of targeted therapeutics, these strains
provide novel platforms for validating new anticancer drugs, assessing therapeutic index, identifying surrogate
markers of tumor progression, and defining epigenetic and environmental influences on tumorigenesis.
The availability of strains of genetically engineered mice (GEM)
that develop a spectrum of cancers similar to those found in
humans offers an unprecedented opportunity to efficiently
evaluate the efficacy and therapeutic index of novel anticancer
therapies in preclinical models in advance of human trials. While
straightforward in principle, executing preclinical studies in mice
that allow for meaningful and immediate application to the treatment of human cancer is difficult. Moreover, the potential use of
GEM cancer models to accelerate the process of bringing effective
new treatments to patients is largely theoretical, as few examples
exist in which mouse preclinical data has been successfully translated to clinical practice.
The current development process for anticancer drugs
Taking a drug from discovery to market is an arduous process
that frequently takes longer than 15 years and costs more than
$800 million. Most agents that are advanced into early-phase
human clinical trials fail. Recent advances in the fields of cancer
biology and high-throughput screening have identified numerous potential molecular targets for drug discovery; however,
most of the proteins and pathways deregulated in cancer cells
also have essential roles in normal cells. It is therefore difficult to
predict when a drug will prove tumor-selective. Moreover, developing new therapies against specific molecular abnormalities in
well-defined subsets of cancers can be prohibitively expensive.
The use of GEM cancer models as an initial “filter” to identify
tumors and molecular targets that, when inhibited, will selectively kill tumor cells is one potential strategy for streamlining
the overall process of cancer drug development.
Preclinical mouse models of human cancer
Numerous small-animal models of human cancer have been generated. These include inbred strains that spontaneously develop
cancer (1–4), rodents in which cancer is caused by intrauterine
or postnatal exposure to chemical mutagens (5–9), and mice in
Nonstandard abbreviations used: APL, acute promyelocytic leukemia; ATRA,
all-trans-retinoic acid; Ftase, farnesyltransferase; FTI, farnesyltransferase inhibitor;
GEM, genetically engineered mouse; MPNST, malignant peripheral nerve sheath
tumor; MTD, maximally tolerated dose; NF1, neurofibromatosis 1; PK/PD, pharmacokinetic and pharmacodynamic; PML, promyelocytic leukemia; RARA, retinoic
acid receptor alpha.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 116:847–852 (2006). doi:10.1172/JCI28271.
The Journal of Clinical Investigation

which tumors are produced by viral or bacterial infection (10–13).
In addition, xenograft models that were generated by directly
implanting cancer cell lines established from human tumors into
mice have been widely used for drug discovery (14–17). The major
limitations of these explant models are the requirement for an
immunocompromised host and the inability of these models to
fully recapitulate the complex relationship between the tumor and
its microenvironment (e.g., angiogenesis). Most importantly, the
ability of xenografts to accurately predict drug efficacy in human
cancer patients has been disappointing (18).
GEM cancer models are becoming increasingly sophisticated
in their ability to accurately mimic the histology and biological
behavior of human cancers. Numerous tissue-specific GEM models have been developed that exhibit many biologic hallmarks of
human cancer, including angiogenesis and stromal interactions,
as well as similar histopathologic and genetic abnormalities (19).
The major advantages of GEM models are that: (a) the initiating
genetic event is known; (b) the mice are immunocompetent; and
(c) the tumors develop spontaneously in their appropriate tissue compartments. Moreover, GEM cancer models, which allow
assessment of therapeutic efficacy on a uniform genetic background, are particularly useful for performing preclinical studies of rare cancers and for assessing synergy between therapeutic
agents. They can also potentially provide the tools needed to learn
more about the histologic and biochemical effects of specific
agents prior to human testing.
While GEM models offer many advantages, the cancers typically arise from genetic events that are expressed simultaneously
in many cells throughout an animal or in an entire tissue. By contrast, most human tumors are believed to arise from single cells or
from a small population of mutant cells. To overcome this limitation, strategies have been developed that allow mutant alleles to be
expressed in small populations of cells in vivo (20, 21).
Opportunities to employ mouse models
The availability of robust GEM models facilitates a detailed analysis of human cancer that cannot be easily accomplished by studying primary human tumors (see Opportunities provided by employing
GEM cancer models). First, the ability to more effectively treat human
cancers requires a detailed understanding of molecular and cellular
pathogenesis to identify specific molecular targets. Second, there
is also a great need to define those individuals at greatest risk for
developing cancer as well as those most likely to respond to any
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given therapeutic regimen. These studies require large numbers
of individuals and are often not possible for less common cancers.
Last, the identification of surrogate markers of tumor formation
and early response to therapy, which would have tremendous
impact on current treatment strategies, is another unmet need.
Evaluation of standard human antitumor therapies. One of the often
neglected uses of GEM cancer models is the validation of conventional therapies employed for the treatment of cognate tumors
in humans. For example, accurate GEM models of astrocytoma
or pancreatic cancer should ideally respond to the same treatments currently used to treat these cancers (i.e., temozolomide
and gemcitibene, respectively). In addition, GEM models afford
the opportunity to define the mechanism(s) underlying the antitumor effects. Tumors from mice treated with anticancer therapies can be analyzed to determine whether regression results from
decreased cell growth, increased cell death, decreased tumor angiogenesis, or necrosis. Failure to observe any effects on GEM tumors
may reflect problems with bioavailability (e.g., inability to cross
the blood-brain barrier), differences in the metabolic processing
of drugs in rodents (e.g., pharmacokinetic and pharmacodynamic
[PK/PD] issues), and/or genetic differences between mouse strains
that dictate the response to therapy (e.g., modifier loci).
Experience with a mouse model of acute promyelocytic leukemia (APL) suggests that GEM models respond to human cancer
treatments and can be used to improve therapy. In APL, blasts
are arrested at the promyelocytic stage of differentiation due to
chromosomal translocations that fuse the retinoic acid receptor alpha
(RARA) gene to a variety of partner genes including promyelocytic
leukemia (PML) and promyelocytic leukemia zinc finger (PLZF). Alltrans-retinoic acid (ATRA) induces complete remissions in approximately 80% of patients with APL who have a PML-RARA translocation by relieving the differentiation block (22) but does not induce
remission in those individuals with PLZF-RARA fusions (23). Similarly, ATRA induces remissions in PML-RARA transgenic mice but
is ineffective in a PLZF-RARA strain that also develops APL (24). In
addition, mouse models of APL have been harnessed to test new
therapeutic approaches such as arsenic trioxide (As2O3) and the
potential synergy between ATRA and As2O3 (25, 26).
The role of specific cancer genes. GEM strains have been generated
that model the inactivation of genes mutated in inherited cancer
syndromes (e.g., neurofibromatosis 1 [NF1], NF2, APC), in sporadic
cancers (e.g., KRAS, PML-RARA), and in both types of cancer (e.g.,
TP53) (27–46). GEM models based on these tumor suppressors
and oncogenes provide unique opportunities to clearly define the
causative role of each of these genetic changes in tumor formation and progression. This information is critical for the design of
targeted (biologically based) therapies for individual cancers with
these specific tumor-associated mutations.

Target validation. GEM cancer models can be used to determine
whether the success or failure of a given therapy reflects the ability
of the drug to reach the tumor and inhibit its target. An illustrative example of how GEM cancer models can provide insights into
mechanisms of drug activity comes from studies that evaluated
the efficacy and putative biochemical targets of farnesyltransferase
(FTase) inhibitors (FTIs). Ras processing is initiated by cytosolic
prenyltransferases, which attach either a farnesyl or geranylgeranyl isoprenoid lipid to the thiol group of the cysteine. Geranylgeranyl transferase 1 (GGTase-1) and FTase catalyze the transfer
of isoprenoid groups, which are donated by geranylgeranyl pyrophosphate and farnesyl pyrophosphate, respectively. FTIs were
developed as cancer therapeutics based on their potential as Ras
inhibitors in xenograft models. However, KRAS and NRAS are
also good GGTase-1 substrates and are processed by this enzyme
when FTase is inhibited. Preclinical studies of the efficacy of FTIs
gave variable results in transgenic mouse models of breast cancer
induced by expressing oncogenic HRAS or KRAS from the murine
mammary tumor virus promoter (47–49) and in a model of myeloproliferative disease induced by inactivating the Nf1 tumor suppressor (50), which encodes a GTPase-activating protein that negatively regulates RAS signaling. Importantly, careful biochemical
investigation of tumor tissues from these mouse models unequivocally showed no inhibition of KRAS or NRAS processing at the
maximally tolerated dose (MTD) of FTI. Based on these data, it
was concluded that any therapeutic effects of FTIs were due to
“off-target” activities that were not related to the original goal of
inhibiting hyperactive RAS.
Defining the discrete steps of tumorigenesis. GEM cancer models can be
used to dissect the cellular and molecular changes associated with
each stage of neoplasia, including tumor formation, tumor maintenance, and malignant progression. Studies focused on defining
the events associated with tumor formation in multistep cancers
are essentially chemoprevention investigations. Direct chemoprevention studies in people at risk for cancer are difficult, owing to
the genetic heterogeneity in human populations and the difficulties in accurately measuring exposure, which necessitate large and
enormously expensive long-term studies. By contrast, experiments
in GEM cancer models can be performed on a uniform genetic
background in which environmental exposures are rigorously controlled. GEM cancer models have been employed to establish causal
relationships with environmental exposures (e.g., asbestos in mesothelioma, tobacco and lung cancer; diet in colon cancer) (51–55).
The ability of a tumor to continue to survive and proliferate in an
otherwise inhospitable environment requires additional molecular
and cellular changes. Studies of tumor maintenance are typically
focused on defining the key signals required for these processes and
form the basis for targeted chemotherapy. Studies in GEM models

Opportunities provided by employing GEM cancer models
Provide initial “filter” to identify molecular targets that, when inhibited, kill cancer cells
Investigate mechanisms underlying responsiveness and resistance to conventional cancer therapies
Define discrete steps of tumorigenesis
Determine the role of the microenvironment in tumor formation and progression
Identify surrogate markers of tumor growth and response to therapy
Define epigenetic and environmental influences on tumorigenesis
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and in human patients have implied that molecular changes important for cancer formation are also necessary for maintenance. For
example, studies in which tetracycline-regulatable alleles of oncogenic RAS and MYC were “shut off” in established tumors resulted
in dramatic tumor regression (56–58). Furthermore, the emergence
of imatinib-resistant mutant alleles of BCR-ABL in patients with
chronic myeloid leukemia (59, 60) argues strongly that the cancerinitiating mutation remains central to the tumor’s growth advantage. However, other data suggest that cancer cells can escape from
dependence on the initiating oncogenic lesion under some circumstances (61, 62). The exact mechanisms underlying “tumor escape”
have not been fully elucidated; but they may reflect a change in the
histologic phenotype of the tumor, loss of expression of the initiating oncogene, or the acquisition of additional genetic changes (63).
The ability of some cancers to free themselves from dependence on
the initiating molecular event likely has implications for the design
of targeted therapies for recurrent tumors.
Tumors frequently evolve from a benign neoplastic lesion to a
more malignant cancer. This progression involves the acquisition
of additional genetic changes, which also serve as targets for chemotherapeutic drug design. For example, during the progression
to malignant cancer, some low-grade astrocytomas somatically
acquire a constitutively active version of the EGFR. This signature
genetic event formed the basis for the development of targeted
therapies directed against this mutant EGFR in both mice and
humans (64, 65). GEM models were important in demonstrating
that the EGFR mutation is a causative genetic change that accelerates malignant transformation (66, 67).
Tumor microenvironment. GEM cancer models have been powerful
tools for examining the contribution of the tumor microenvironment to tumor formation. Studies of peripheral and central nervous system tumors in a mouse model of the NF1 familial cancer
syndrome demonstrated that tumor formation requires that loss
of Nf1 expression in Schwann cells (neurofibromas) or astrocytes
(optic glioma) occur in the context of a heterozygous germline Nf1
mutation (43, 44). These data demonstrate that heterozygous Nf1
mutant cells in the microenvironment of preneoplastic lesions
participate in tumorigenesis. Nonmalignant stromal cells also contribute to mammary carcinoma, in which loss of TGF-β receptor
expression in fibroblasts promotes mammary ductal carcinoma
growth and invasion by upregulating specific signaling networks
(68, 69). Last, angiogenesis plays a fundamental role in tumor formation and progression and has formed the biological basis for
numerous clinical trials using antiangiogenic therapies (70, 71).
GEM models have been instructive in defining the molecular basis
for new blood vessel formation by tumors and the impact of angiogenesis on tumor progression (72, 73).
Radiologic and serum biomarkers. The ability to define individuals
at high risk of developing cancer and the ability to noninvasively
monitor disease burden during and after cancer treatment have
substantial implications for clinical practice. GEM models have
been employed to identify serum biomarkers for cancer using
advanced proteomics methods. While these studies are still in their
early phases of discovery, one serum biomarker has been identified
for murine prostate cancer that correlated well with tumor weight
and response to hormone therapy (74). In addition to serum biomarkers, MRI has recently been evaluated for its ability to provide
information regarding therapeutic efficacy in brain tumors. MRI
of mice bearing brain tumors demonstrated that the tissue diffusion values obtained early after standard chemotherapy correlated
The Journal of Clinical Investigation

with tumor response (75). These results prompted an investigation
of human brain tumors, which showed that tissue diffusion values
obtained 3 weeks after the initiation of chemotherapy could predict patient response (76). Similar to serum biomarkers, the ability
of MRI to define patients with recurrent disease or who do not
respond to first-line therapy would allow for early intervention
and the administration of alternative therapies.
Modifier genes. Unlike humans, GEM models can be generated
on homogeneous genetic backgrounds, which greatly facilitate
identifying modifier genes that influence the incidence or clinical behavior of specific cancers. Numerous candidate genetic loci
have been found that influence tumor number and size in mouse
lung and colon cancer (77–79) as well as tumor type in mice
harboring identical genetic mutations. For example, the tumor
spectrum in mice harboring mutations in the p53 and Nf1 genes
is dictated by the genetic background, which led to the identification of a locus on mouse chromosome 11 that determined
susceptibility to astrocytoma (80). Last, genes that function to
identify DNA polymerase errors during DNA replication (DNA
mismatch repair genes) have been shown to modify colon cancer
tumor burden and survival in GEM (81–83).
Performing preclinical studies in mice
Evaluating conventional cancer therapies in human patients. There
are well-established paradigms for testing new drugs in human
patients. New agents are typically evaluated in 3 phases. As the
primary goal of a phase 1 trial is to determine the MTD of a drug,
these studies typically involve administering a single agent to
patients with a variety of different tumor types who have failed
to respond to standard therapies. Phase 2 trials are designed to
measure response rates in a group of patients with refractory or
recurrent cancers treated at the MTD. Responses are traditionally reported as “complete” (objective regression of all detectable
lesions), “partial” (some regression), or “mixed” (regression of
some lesions with growth of others). Compounds that show significant promise in phase 2 studies are advanced to randomized
phase 3 trials, in which the new drug is compared, either alone or
in combination with other agents, to the “standard” treatment for
a specific cancer. In contrast to phase 1 and phase 2 trials, phase 3
studies include newly diagnosed patients and are frequently performed in the setting of cooperative multi-institutional networks.
Because phase 2 and phase 3 studies are logistically challenging,
expensive, and time consuming, pharmaceutical and biotechnology companies are understandably most interested in testing
agents that might be approved to treat patients with common
cancers. Importantly, phase 1 trials in patients with refractory
cancers may not accurately mimic response rates in persons with
de novo disease, and it has been difficult to test drug combinations in phase 1 and phase 2 trials. GEM cancer models offer the
possibility of overcoming these 2 problems.
Using GEM cancer models to investigate responsiveness and resistance
to conventional anticancer agents. Relatively few studies of conventional cytotoxic agents have been performed in GEM models.
This is due, in part, to the fact that many investigators who generate GEM cancer models lack expertise in performing preclinical studies. Although much less expensive than human clinical
trials, investigating drugs in mice is challenging due to factors
that include the need to generate and maintain cohorts of mice
that spontaneously develop tumors, difficulties in assessing the
responses of tumors that can only be visualized by small-animal
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Figure 1
Use of GEM tumor models as “filters” to select agents for human clinical trials. One strategy has been proposed for use in the Nf1 GEM
models community, which involves the evaluation of new therapies in
multiple mouse strains. New drugs would be rapidly screened using
MPNST and leukemia GEM models for efficacy (therapeutic index),
target validation, and potential “off-target” effects. These GEM models
would be utilized for initial evaluation, based on the rapid growth of the
tumors and the relative ease of measuring tumor growth. Drugs that
exhibit activity in these models would be further analyzed in detailed
PK/PD studies in other tumor models, such as orthotopic tumor explant
models and transgenic mice harboring specific deregulated cancerassociated molecules or pathways. Optic glioma and neurofibroma
(plexiform neurofibroma) GEM models may be better suited for chemoprevention studies as well as investigations of drugs that target
specific cells in the tumor microenvironment (e.g., microglia and mast
cells). Collectively, the combined use of each of the available robust
preclinical GEM models would afford researchers the opportunity to
comprehensively evaluate drugs prior to considering human clinical
trials. Adapted with permission from a summary presentation by Susan
Blaney, Cold Spring Harbor Laboratories, Banbury Center conference
on “Barriers and Solutions in the Use of Mouse Models to Develop
Therapeutic Strategies for Neurofibromatosis-Associated Tumors,”
November 3–5, 2005.

imaging (e.g., MRI), and the limited availability of laboratory support to measure PK/PD endpoints. Similarly, it is important to
understand why some human tumors are inherently insensitive
to chemotherapeutic agents, while other cancers initially respond
but later become resistant when patients relapse. Pioneering studies in an Eµ-Myc B cell lymphoma model have shown that some of
the genetic lesions that contribute to cancer, such as Tp53 inactivation or deregulated Bcl2 expression, also modulate resistance to
chemotherapeutic agents (84, 85).
Evaluating molecularly targeted inhibitors in humans and in GEM
models. Some traditional strategies for evaluating new cancer therapeutics are being reconsidered as more specific agents are developed (86). Target inhibition, rather than overt clinical toxicity
(e.g., MTD), may represent a better endpoint for phase 1 testing of
drugs with a well-defined biochemical target. Additionally, there
are now many examples that underscore the importance of preselecting patients with specific molecular abnormalities for targeted therapies trials. In this regard, the beneficial effects of ATRA
850
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are largely limited to APL; the efficacy of imatinib correlates with
biochemical inhibition of specific mutant kinases (BCR-ABL, ckit, and PDGF); and the presence of activating EGFR mutations
predicts clinical responsiveness to gefitinib in lung cancer (25,
87–91). In a recent study, coexpression of a mutant EGFR receptor and an intact PTEN gene correlated with the response of highgrade malignant astrocytoma to EGFR inhibitors (92). Similarly,
although RAS and BRAF mutations both encode proteins that
deregulate MEK/ERK signaling in melanoma, cancer cell lines
with BRAF mutations are highly sensitive to MEK inhibitors,
whereas cells with RAS mutations are not (93).
Harnessing GEM cancer models to enhance the development of new
therapies. Academic researchers, pharmaceutical companies, government agencies, and patient advocacy groups have all expressed
concern about the apparent “disconnect” between our growing
understanding of cancer biology and the relatively few instances
in which these advances have been successfully translated into
better cancer treatments. The authors recently participated in a
meeting that examined how mouse models of tumors that develop
in persons with NF1 and NF2 could be efficiently employed to
inform human clinical trials (“Barriers and Solutions in the Use
of Mouse Models to Develop Therapeutic Strategies for Neurofibromatosis-Associated Tumors,” Banbury Center, Cold Spring
Harbor Laboratories, November 3–5, 2005). Individuals with NF1
are predisposed to the development of specific benign and malignant tumors, including cutaneous and plexiform neurofibromas, low-grade astrocytoma, juvenile myelomonocytic leukemia
(JMML), and malignant peripheral nerve sheath tumor (MPNST),
while persons with NF2 develop schwannoma, meningioma, and
ependymoma (94). Because NF1- and NF2-associated tumors are
relatively uncommon, pharmaceutical and biotechnology companies are not actively engaged in developing drugs for these specific
indications. However, the molecular genetics of human NF1 and
NF2 are understood in detail, and elegant mouse models of most
NF-associated tumors are available. Many companies are developing drugs that interfere with components of the RAS signaling
network, which might prove effective in some NF1-associated
tumors. Unfortunately, performing clinical trials in NF1 patients
is difficult for a variety of reasons, including the slow and predictable growth rates of many of these tumors, the propensity to affect
children, and relatively small patient numbers. GEM models of
JMML and MPNST are characterized by rapid growth and relative
ease of measuring treatment responses (45, 46, 95, 96). These in
vivo models, and tumor cells from these mice, could be used to
rapidly screen candidate drugs for a beneficial therapeutic index,
and promising agents might be investigated further by performing detailed PK/PD studies. By contrast, evaluating therapeutics in
the existing neurofibroma and optic glioma GEM models is more
difficult due to their relatively slow growth rates and requirement
for small-animal imaging (43, 44). These models might be more
useful for studies of preventive agents or for “front-line” preclinical studies of compounds that target cells in the tumor microenvironment. The overall goal of this type of strategy (Figure 1) is to
optimally employ the available GEM tumor models as “filters” to
select agents for human trials that have the greatest likelihood of
succeeding in the clinic. In this proposed strategy, new drugs could
be rapidly screened for efficacy, target validation, and potential
“off-target” effects in GEM models that lend themselves well to
rapid throughput (e.g., Nf1 MPNST and leukemia GEM models).
Drugs active in these paradigms would be further studied to define
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their bioavailability and pharmacokinetics in other GEM model
systems (e.g., orthotopic transplant or transgenic mouse models).
Secondary evaluation of candidate drugs would then entail the
use of additional GEM strains (e.g., Nf1 optic glioma and neurofibroma GEM models) in which tumor microenvironment plays an
important role in cancer formation. These latter GEM models are
uniquely suited for chemoprevention studies as well as for examining drugs directed against specific cell types in the tumor microenvironment (e.g., immune system cells, endothelial cells). The combined use of multiple complementary preclinical model systems
provides an excellent opportunity to comprehensively evaluate
lead compounds under conditions that closely approximate the
human condition prior to the initiation of human clinical trials.
Given the pressing need to develop new cancer therapies, it is
important to establish preclinical testing paradigms that provide
the greatest opportunities to optimally translate results obtained
in GEM cancer models into the clinic. We recommend that investigators take advantage of the multiple complementary GEM can1. Lubet, R.A., Zhang, Z., Wang, Y., and You, M. 2004.
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